The time to practically use Sugammadex throughout Korea has come.

It might be right time when we contemplate the clinical use of sugammadex carefully.

Sugammadex is a modified gamma-cyclodextrin which is showing favorable outcomes regarding the reversal of neuromuscular blockade, especially by rocuronium. It is designed to encapsulate rocuronium and providing a rapid reversal from the neuromuscular block. It becomes a new class of drugs as selective relaxant binding agents \[[@B1]\] and is currently available for over 50 countries \[[@B2]\].

The dose for the reversal of moderate block (at two TOF responses) is known to be 2 mg/kg, 4 to 8 mg/kg for a profound block (a level of two post-tetanic responses) and a dose of 16 mg/kg for immediate rescue reversal \[[@B3]-[@B5]\]. Sugammadex has provided countless benefits to patients at risk of incomplete or delayed recovery after neuromuscular block accordingly. This new drug received reviewed as a milestone in anesthesia with high praise according to the unrivaled mechanism of drug action \[[@B4]\]. Current available data strongly bring to mind that sugammadex for regular use might have the potential to shorten recovery times. Although titrated administered neuromuscular blockades could be perceived in clinical routine, increased recovery times after reversal with acetylcholine inhibitors are not usually discerned when neuromuscular monitoring is waived. Therefore, the exclusive ability of sugammadex to antagonize any degree of residual neuromuscular block effectively and affirmatively could prevent untimely extubation related to the acetylcholine inhibitor based reversal.

The accepted current concept of a TOF ratio of 0.9 is favorable for satisfactory recovery as safe with regard to the risk of recurarization problems \[[@B3]\]. Post-operative respiratory and airway problems were not satisfactory until the adductor pollicis TOF ratio reached 0.9 \[[@B6]\]. 98% of the patients were recovered within 5 minutes after 2 mg/kg sugammadex and the recovery from the neuromuscular block of rocuronium to a TOF ratio of 0.9 is around 13 times faster with sugammadex compared to the conventional neostigmine \[[@B7]\].

However, some questions related to the twitch characteristics remain and require further investigation.

The use of sugammadex for deep blockades had shown to report an interesting phenomenon. The TOF recovery before complete recovery of single twitch had a difference of up to 5 minutes between the types of stimulation \[[@B8]\]. This study demonstrated that after reversal of rocuronium-induced neuromuscular block by sugammadex, the return of a normal TOF ratio can precede the return of a normal twitch height, dose-dependently. According to those results, the traditional relationship between TOF ratio and T1 recovery may not be valid anymore. The recovery of the TOF ratio to 0.9 precedes the recovery of T1, and the TOF ratio might be fully recovered not for T1. Therefore, the TOF ratio may no longer be the only measurement concept regarding adequate reversal after reversal with sugammadex. The twitch height has to be considered with the TOF ratio in this case. Moreover, it is interesting that this response has a point of similarity as the pattern of a partial succinylcholine block as depression of T1 with the continuation of TOF.

This phenomenon will be further investigated in the near future from not only the complete reversal considered with the presence of T1 depression, but also in regards to the unique characteristics of sugammadex reversal.

Secondly, the effect of sugammadex on which the eyes rested is anaphylaxis.

Allergic reactions to neuromuscular blockades are the most common cause of anaphylaxis in general anesthesia. Rocuronium and succinylcholine were the most common agents related with anaphylaxis \[[@B9]\]. Cisatracurium as the representative drug of benzylisoqunolinium also cannot be free from the allergic reaction. Kounis syndrome \[[@B10]\], anaphylaxis after negative skin test \[[@B11]\] and anaphylactoid reactions \[[@B12]\] were reported.

Jones and Turkstra \[[@B13]\] first described that sugammadex might be used to eliminate rocuronium from the circulation of the one who had rocuronium induced anaphylaxis and then stop or delay the immunologic progression cascades. There are several uncertainties regarding this strategy. Responsible parts of the rocuronium molecule for anaphylaxis are not known. Involvement of the IgE antibody to rocuronium, the differences of plasma half-life between the sugammadex-rocuronium complex and the rocuronium molecule itself, the attachments by the exposed part of the rocuronium molecule after the complex formation according to the allergenic determinant and the interrelationships of binding among rocuronium, sugammadex and IgE antibodies need to be revealed, Since anaphylaxis is widely known for its continuence after removal of the target allergen.

Lastly, there are reported issues relevant to the allergic reaction of sugammadex with regards to the clinical dosages \[[@B14]-[@B17]\]. Five cases were reported from Japan \[[@B14],[@B15],[@B17]\]. Of the cases, four involved females, and one case involving a male was reported from Spain \[[@B16]\]. At the high dose range (32-96 mg/kg), one healthy Dutchman reported suffering from possible hypersensitivity to sugammadex \[[@B18]\].

In the in vitro rat model, sugammadex itself did not directly affect the contractile function in bronchial smooth muscles \[[@B19]\]. However, among the patients with pulmonary disease, it was reported that 2 out of 77 American patients (2.6%) represented bronchospasm after sugammadex \[[@B20]\]. Those two patients had a history of asthma and belonged to the 4 mg/kg group. The mechanism was unclear and not explained in the article but bronchial smooth muscle hyperresponsiveness might be involved.

So if the time comes when we demand a change, we will all know how to make it happen. Problems often arise from small simple mistakes much like the way a wall crumbles from plants growing in the interstices between bricks.

Anesthesiologists need to be more vigilant in using sugammadex for clinical practice.

The patient\'s history of pulmonary disease and allergic disease are key considerations when contemplating the use of sugammadex.
